Most complete
Wall Street analysis
The complete report: valuation, financials, and competitive position, built with the same framework professional analysts use.
Johnson & Johnson (JNJ)Professional Stock Analysis
Deep financial insights, market sentiment, and technical indicators. For less than a coffee ☕
Analysis types
Pick what you want to know
Each report answers a different question about the stock, from financial health to long-term growth. The credit cost is shown next to every option in the form.
Financials
Deep financial breakdown
Revenue trends, profit margins, cash flow health, and balance sheet strength, so you understand the financial foundation of any stock.
Moat
Competitive advantage
Find out if the company has a lasting edge over competitors: brand power, network effects, switching costs, and cost advantages.
Risk
Risk analysis
Uncover hidden risks including debt exposure, regulatory threats, management concerns, and macroeconomic vulnerabilities.
Growth
Growth potential
Assess future growth drivers such as market expansion, product pipelines, international reach, and emerging sector trends.
How Johnson & Johnson makes money
Johnson & Johnson is a diversified healthcare company operating in two segments after spinning off its consumer-health unit (Kenvue): Innovative Medicine (branded pharmaceuticals) and MedTech (medical devices). Patent-protected drugs and a broad device portfolio generate stable, defensive cash flows.
Key products and revenue lines
- Innovative Medicine: oncology, immunology, and neuroscience drugs
- MedTech: surgical, orthopaedics, cardiovascular, and vision devices
- Pharmaceutical pipeline therapies
The bull and bear case for JNJ
Bulls view J&J as a defensive, high-quality healthcare compounder with a diversified drug and device portfolio, a deep pipeline, and a long record of dividend increases (a Dividend King).
Bears focus on patent-cliff risk for key drugs (notably biosimilar competition for Stelara), the talc-related litigation overhang, and the slower growth typical of large-cap pharma.
Key risks for Johnson & Johnson investors
- Patent cliffs and biosimilar competition for major drugs
- Talc and other product-liability litigation
- Drug-pricing regulation and reform
- Pipeline and clinical-trial setbacks
What to watch next
Watch pharmaceutical pipeline progress and new-drug launches offsetting patent expiries, MedTech growth, litigation resolution, and dividend growth. Operating-margin stability signals quality.
Who Johnson & Johnson competes with
Johnson & Johnson operates in the Healthcare sector and competes most directly with Pfizer, Merck, AbbVie, Medtronic, Abbott Laboratories. Comparing a company against its own peer group matters more than reading its metrics in isolation: a valuation multiple, a margin, or a growth rate only means something relative to the alternatives an investor could buy instead.
Further reading
- How Dividends Actually Work: Ex-Dates, Payouts, and ReinvestmentBuying a stock the day before its dividend does not get you free money; the price adjusts to the cent. Here is the full mechanics of dividends, from declaration to reinvestment.
- How to Assess Stock Risk Before You InvestThe goal is not to avoid risk; it is to get paid enough for taking it. Here is how professionals separate the risks that dent a quarter from the ones that destroy a thesis.
- Dividend Growth Investing: Why a Rising 2% Beats a Static 6%Income investors instinctively chase the biggest yield. The long-run data favours the smaller dividend that grows, and the math of yield-on-cost shows exactly why.
Frequently asked questions about Johnson & Johnson (JNJ)
What is Johnson & Johnson (JNJ)?
Johnson & Johnson is a diversified healthcare company operating in two segments after spinning off its consumer-health unit (Kenvue): Innovative Medicine (branded pharmaceuticals) and MedTech (medical devices). Patent-protected drugs and a broad device portfolio generate stable, defensive cash flows.
Is Johnson & Johnson (JNJ) a good investment?
Whether Johnson & Johnson is a good investment depends on your strategy and risk tolerance. Watch pharmaceutical pipeline progress and new-drug launches offsetting patent expiries, MedTech growth, litigation resolution, and dividend growth. Operating-margin stability signals quality. This is educational information, not investment advice.
What are the main risks of investing in Johnson & Johnson stock?
Key risks for Johnson & Johnson (JNJ) include: Patent cliffs and biosimilar competition for major drugs; Talc and other product-liability litigation; Drug-pricing regulation and reform; Pipeline and clinical-trial setbacks.
Who are Johnson & Johnson's main competitors?
Johnson & Johnson (JNJ) operates in the Healthcare sector and competes with Pfizer, Merck, AbbVie, Medtronic, Abbott Laboratories.
What is a patent cliff?
Branded drugs are protected by patents for a fixed period. When protection lapses, generic or biosimilar versions enter at much lower prices and the original product can lose most of its revenue within a couple of years. Because that revenue carried very high margins, the profit impact is larger than the revenue impact, and it arrives on a known date, which is why pipelines are valued against scheduled expiries.
What was the Kenvue spin-off?
Johnson & Johnson separated its consumer-health business, the household brands sold over the counter, into an independent company called Kenvue. What remains is a focused pharmaceutical and medical-device company with higher growth and higher risk: consumer health was the slowest-growing but most predictable part of the old group.
How should investors think about the talc litigation?
Product-liability litigation of this scale creates an overhang because the eventual cost and timing are both unknown, and markets discount uncertainty more harshly than they discount a large but defined liability. Resolution tends to matter to the share price out of proportion to the amount finally paid.